Infensa Bioscience

First-in-class drugs with addressable worldwide market of tens of millions of patients per year who suffer heart attack or stroke. Ability of a single drug class to address multiple diseases enables staged clinical development with continuous value creation. Other potential indications: traumatic head injury, hypoxic brain injury (cerebral palsy), retinal artery thrombosis, kidney artery thrombosis, cardiac and brain surgery, endarterectomy and heart valve replacement. Key asset protected by patents granted globally

Pharmaceutical,molecules,peptide,hi1a,research,heart attack,stroke,ischemic,start up,blood,brain,venom,and spider

Infensa bioscience operates in the Biotechnology research industry.

Infensa bioscience's revenue is 11m - 100m

Infensa bioscience has 11 - 50 employees.